Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis-Reference-Cited by-同舟云学术

Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis

Published:2019-12-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Grace Angeline G¹,Mittal Abhenil²,Jain Siddharth³,Tripathy Jaya P⁴,Satyanarayana Srinath⁵,Tharyan Prathap⁶,Kirubakaran Richard⁷

Affiliation:

1. Sree Balaji Medical College & Hospital; Department of Community Medicine; Works road Chrompet Chennai India 600044

2. All India Institute of Medical Sciences; Department of Internal Medicine; New Delhi India

3. Postgraduate Institute of Medical Education and Research (PGIMER); Clinical Immunology and Rheumatology Unit, Department of Internal Medicine; Chandigarh India 160012

4. International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office; Centre for Operational Research; New Delhi India

5. International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office; New Delhi India

6. Christian Medical College; Clinical Epidemiology Unit, Prof. BV Moses Centre for Evidence-Informed Healthcare and Health Policy; Carman Block II Floor CMC Campus, Bagayam Vellore Tamil Nadu India 632002

7. Christian Medical College; Cochrane South Asia, Prof. BV Moses Centre for Evidence-Informed Healthcare and Health Policy; Carman Block II Floor CMC Campus, Bagayam Vellore India 632002

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012918.pub2/epdf/full

Reference99 articles.

1. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis;Gillespie;New England Journal of Medicine,2014

2. NCT00864383 Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB) https://clinicaltrials.gov/ct2/show/NCT00864383

3. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials;Phillips;BMC Medicine,2016

4. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens;Phillips;BMC Medicine,2017

5. CTRI/2012/10/003060 A study of the efficacy and tolerability of moxifloxacin and gatifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=5124&EncHid=&userName=CTRI/2012/10/003060

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Mechanism of Mycobacterial (p)ppGpp Synthetase Inhibition by Synthetic Erogorgiaene Analog;Биохимия;2024-09-14

2. Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury;Pharmacogenomics;2024-09-12

3. Syndrome of Inappropriate Antidiuretic Hormone and Antituberculosis Treatment-induced Hepatitis: A Case Report;Indian Journal of Respiratory Care;2024-06-18

4. Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis;Frontiers in Immunology;2024-06-03

5. Efficacy and Safety Rifapentine-Containing Regimen for Drug Sensitive Tuberculosis: Systematic Review and Meta-Analysis;Pneumon;2024-04-26